{
    "organizations": [],
    "uuid": "9fd3aa2718dd85f4dfedd461ca77228e6b0212cf",
    "author": "",
    "url": "https://www.reuters.com/article/brief-ligand-enters-into-agreement-with/brief-ligand-enters-into-agreement-with-venbio-idUSFWN1RC02W",
    "ord_in_thread": 0,
    "title": "BRIEF-Ligand Enters Into Agreement With venBio",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 30, 2018 / 1:28 PM / Updated 11 minutes ago BRIEF-Ligand Enters Into Agreement With venBio Reuters Staff 1 Min Read \nMarch 30 (Reuters) - Ligand Pharmaceuticals Inc: \n* LIGAND ENTERS INTO AGREEMENT WITH VENBIO TO MAKE WORLDWIDE OMNIABÂ® PLATFORM LICENSE ACCESSIBLE TO PORTFOLIO COMPANIES Source text for Eikon: Further company coverage:",
    "published": "2018-03-30T16:28:00.000+03:00",
    "crawled": "2018-03-30T16:43:34.004+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "pm",
        "updated",
        "minute",
        "ago",
        "enters",
        "agreement",
        "venbio",
        "reuters",
        "staff",
        "min",
        "read",
        "march",
        "reuters",
        "ligand",
        "pharmaceutical",
        "inc",
        "ligand",
        "enters",
        "agreement",
        "venbio",
        "make",
        "worldwide",
        "platform",
        "license",
        "accessible",
        "portfolio",
        "company",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}